10
Participants
Start Date
December 15, 2020
Primary Completion Date
July 1, 2023
Study Completion Date
July 1, 2023
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)
A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
Standard initiation of antiretroviral therapy (ART)
Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
University of Nebraska, Omaha
Children's Hospital Colorado, Aurora
University of Colorado Anschutz, Aurora
Collaborators (1)
Gilead Sciences
INDUSTRY
University of Colorado, Denver
OTHER